Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009

Health Policy and Technology

Volumn 3, Issue 1, 2014, Pages 36-58

  Lichtenberg, Frank R ^a  

^a NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Innovation; Longevity; Mortality; Pharmaceuticals

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BIRTH RATE; DEVELOPING COUNTRY; EDUCATIONAL STATUS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HIGH INCOME GROUP; INFECTION RISK; LIFE EXPECTANCY; POPULATION GROWTH; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SOCIAL STATUS; SOCIOECONOMICS; SURVIVAL RATE; UNEMPLOYMENT; UNITED STATES; URBANIZATION;

EID: 84892991693     PISSN: 22118837     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlpt.2013.09.005     Document Type: Article

References (37)

1. Acemoglu D., Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Q J Econ 2004, 119(3):1049-1090.
2. Almond D, Mazumder B. How did schooling laws improve long-term health and lower mortalityα Federal Reserve Bank of Chicago. Working Paper No WP-06-23 ; 2006. http://www.chicagofed.org/publications/workingpapers/wp2006_23.pdf.
3. Bahk B., Gort M. Decomposing learning by doing in new plants. J Political Econ 1993, 101:561-583.
4. Bresnahan TF, Gordon RJ., The economics of new goods University of Chicago Press; 1996. Chicago.
5. Center for Medicare and Medicaid Services. National Health Expenditure Data, ; 2013. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/tables.pdf.
6. Cerda R.A. Endogenous innovations in the pharmaceutical industry. J Evol Econ 2007, 17:473-515.
7. Civan A., Maloney M.T. The determinants of pharmaceutical research and development investments. Contrib Econ Anal Policy 2006, 5(1). (Article 28).
8. Cutler D., Deaton A., Lleras-Muney A. The determinants of mortality. J Econ Perspect 2006, 20:97-120.
9. Danzon P., Wang Y.R., Wang L. The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s. Health Econ 2005, 14(3):269-292.
10. Deaton A., Paxson C. Mortality, income, and income inequality over time in Britain and the United States. Perspectives on the economics of aging 2004, 247-280. University of Chicago Press, Chicago. D.A. Wise (Ed.).
11. Dorsey E.R., de Roulet J., Thompson J.P., Reminick J.I., Thai A., White-Stellato Z., et al. Financial anatomy of biomedical research, 2003-2008. J Am Med Assoc 2010, 303(2):137-143.
12. Food and Drug Administration. Drug and Biologic Approval Reports. NDA approvals by therapeutic potential and chemical type, ; 2013. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121102.htm.
13. Ford E.S., Ajani U.A., Croft J.B., Critchley J.A., Labarthe D.R., Kottke T.E., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356:2388-2398.
14. Flegal K.M., Graubard B.I., Williamson D.F., Gail M.H. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005, 293:1861-1867.
15. Harris G., Thomas K. Low-cost drugs in poor nations get a lift in Indian court 2013, New York Times, New York.
16. Hercowitz Z. The 'embodiment' controversy: a review essay. J Monetary Econ 1998, 41:217-224.
17. Hulten C.R. Growth accounting when technical change is embodied in capital. Am Econ Rev 1992, 82(4):964-980.
18. Leon D.A. Cities, urbanization and health. Int J Epidemiol 2008, 37:4-8.
19. Lichtenberg F.R. Pharmaceutical innovation and the burden of disease in developing countries. J Med Philos 2005, 30(6).
20. Lichtenberg F.R. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int J Health Care Finance Econ 2005, 5:47-73.
21. Lichtenberg F.R. The quality of medical care, behavioral risk factors, and longevity growth. Int J Health Care Finance Econ 2011, 11(1):1-34.
22. Lichtenberg F.R. The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-2007. PharmacoEconomics 2012, 30(3):197-211.
23. Lichtenberg F.R. The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 2000-2007. Soc Sci Med 2013, 77:50-59.
24. Lichtenberg F.R. The effect of pharmaceutical innovation on longevity: patient level evidence from the 1996-2002 medical expenditure panel survey and linked mortality public-use files. Forum Health Econ Policy 2013, 16(1):1-33.
25. Lichtenberg FR. 2013c, "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009, Econ Hum Biol, Available from 12 April, http://www.sciencedirect.com/science/article/pii/S1570677X13000373.
26. Lichtenberg F.R., Duflos G. Pharmaceutical innovation and the longevity of Australians: a first look, with Gautier Duflos. Adv Health Econ Health Serv Res 2008, 19:95-117.
27. Lichtenberg F.R., Grootendorst P., Van Audenrode M., Latremouille-Viau D., Lefebvre P. The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data. Value in Health 2009, 12(6):847-856.
28. Lleras-Muney A The relationship between education and adult mortality in the United States. Rev Econ Stud 2005, 72(1):189-221.
29. Murphy K.M., Topel R.H. The value of health and longevity. J Political Econ 2006, 114(4):871-904.
30. National Science Foundation. U.S. Corporate R&D: Volume 1: Top 500 Firms in R&D by Industry Category, ; 2012. http://www.nsf.gov/statistics/nsf00301/expendit.htm.
31. Nordhaus W.D. The Health of nations: the contribution of improved health to living standards. Measuring the gains from medical research: an economic approach 2003, 9-40. University of Chicago Press, Chicago. K.M. Murphy, R.H. Topel (Eds.).
32. Romer P. Endogenous technological change. J Political Econ 1990, 98(5, Part 2):S71-S102.
33. Ruhm C.J. Healthy living in hard times. J Health Econ 2005, 24:341-363.
34. Sakellaris P., Wilson D. Quantifying embodied technological change. Rev Econ Dyn 2004, 7(1):1-26.
35. Sampat B.N., Lichtenberg F.R. What are the respective roles of the public and private sectors in pharmaceutical innovationα. Health Aff 2011, 30(2):332-339.
36. Solow R.M. Investment and technological progress. Mathematical methods in social sciences 1959 1960, 89-104. Stanford University Press, Stanford. K. Arrow, S. Karlin, P. Suppes (Eds.).
37. World Health Organization. Life tables for 2009, 2000 and 1990: summary of data and methods used. May, ; 2012. http://www.who.int/healthinfo/statistics/LT_method.pdf.